Feedback
Settings

Settings

Goto Application

295,679 results
Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 29,568
1.WO/2021/009332METHOD FOR DECREASING ADVERSE-EFFECTS OF INTERFERON
WO - 21.01.2021
Int.Class A61K 38/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons
 Appl.No PCT/EP2020/070240 Applicant ENYO PHARMA Inventor VONDERSCHER, Jacky
The present invention relates to a method for decreasing adverse-effects of interferon and to new compositions and methods of treatment.
2.WO/2021/009662COMPOSITIONS FOR TREATMENT OF INFERTILITY CAUSED BY POOR SEMEN QUALITY, METHODS FOR PREPARING THE SAME AND APPLICATIONS THEREOF
WO - 21.01.2021
Int.Class A61K 38/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
 Appl.No PCT/IB2020/056579 Applicant PALANIVEL, Vasanthi Inventor PALANIVEL, Vasanthi
The present disclosure generally relates to the field of infertility, and in particular male infertility. Accordingly, the present disclosure provides for compositions and methods for managing male infertility, caused by poor semen quality. More particularly, the present disclosure provides a therapeutic composition comprising a platelet rich plasma (PRP) or a growth factor concentrate derived therefrom and a thermoresponsive polymer. The present disclosure also relates to the compositions of PRP and the concentrate themselves. Consequently, methods to obtain the said compositions, along with therapeutic applications for treatment of infertility caused by poor semen quality are also provided.
3.WO/2021/009692TRIPARTITE SYSTEMS FOR PROTEIN DIMERIZATION AND METHODS OF USE
WO - 21.01.2021
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
 Appl.No PCT/IB2020/056657 Applicant MEDIMMUNE LIMITED Inventor BAMBER, Lisa
The disclosure provides compositions and methods that make use of a target protein that is capable of binding to a small molecule in order to form a complex, and a binding member that specifically binds to the complex, wherein the target protein is derived from a non-human protein and the small molecule is an inhibitor of the non-human protein. The non-human protein may be derived from a viral, bacterial, fungal or protozoal protein. These compositions and methods permit the controlled interaction of polypeptides that are individually fused to the target protein and binding member, respectively, and can be used to control the activity of dimerization-inducible proteins such as split transcription factors and split chimeric antigen receptors through the addition of the small molecule. The disclosure provides expression vectors, binding members, dimerization-inducible proteins, nucleic acids, cells, viral particles, kits, systems and methods that involve these components.
4.WO/2021/010532METHOD FOR PREPARING LONG-ACTING DRUG CONJUGATE THROUGH PREPARATION OF NOVEL INTERMEDIATE
WO - 21.01.2021
Int.Class C07K 14/575
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
 Appl.No PCT/KR2019/008912 Applicant HANMI PHARM. CO., LTD. Inventor SHIN, Cheongbyeol
The present invention relates to a novel method for preparing a long-acting drug conjugate, and a long-acting drug conjugate prepared by the method.
5.WO/2021/011912COMBINATION OF INTEGRIN-TARGETING KNOTTIN-FC FUSION AND ANTI-CD47 ANTIBODY FOR THE TREATMENT OF CANCER
WO - 21.01.2021
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No PCT/US2020/042644 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor COCHRAN, Jennifer R.
The present invention provides a method of treating cancer with an integrin-binding-Fc fusion protein in combination with an SIRPα-CD47 immune checkpoint inhibitor, for example an anti-CD47 antibody or an anti-SIRPα-antibody. The invention also provides composition for use in such methods.
6.WO/2021/009331IMPROVED TREATMENT USING EYP001
WO - 21.01.2021
Int.Class A61K 38/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons
 Appl.No PCT/EP2020/070239 Applicant ENYO PHARMA Inventor VONDERSCHER, Jacky
The present invention relates to a method of treatment with an FXR agonist allowing to decrease pruritus and improve efficacy.
7.WO/2021/010531NOVEL METHOD FOR PREPARING PROTEIN CONJUGATE
WO - 21.01.2021
Int.Class C07K 14/575
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
 Appl.No PCT/KR2019/008911 Applicant HANMI PHARM. CO., LTD. Inventor SHIN, Cheongbyeol
The present invention relates to a novel method for preparing a protein conjugate, and a protein conjugate prepared by the method.
8.WO/2021/009247IMPROVING CAS NUCLEASE TARGET SPECIFICITY
WO - 21.01.2021
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/EP2020/070031 Applicant DEUTSCHES KREBSFORSCHUNGSZENTRUM Inventor ASCHENBRENNER, Sabine
The present invention relates to a method for modifying a target site in a host cell comprising contacting said host cell with a Cas nuclease, wherein said host cell is further contacted with a low-affinity Cas inhibitor and/or a sub-inhibitory concentration of a Cas inhibitor; and to a method for improving specificity of a Cas nuclease, comprising a) providing a Cas nuclease; and b) contacting said Cas nuclease with a low-affinity Cas inhibitor or a sub-inhibitory concentration of a Cas inhibitor; and c) thereby improving specificity of said Cas enzyme. Further, the present invention relates to compositions, polypeptides, uses and methods related thereto.
9.WO/2021/010702COMPOSITION FOR REGENERATING GROWTH PLATE
WO - 21.01.2021
Int.Class A61K 35/32
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
 Appl.No PCT/KR2020/009179 Applicant AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION Inventor MIN, Byoung-Hyun
The present invention provides a composition comprising fetal cartilage tissue-derived cells and a fetal cartilage tissue-derived extracellular matrix as active ingredients for regenerating a growth plate. The composition for regenerating a growth plate can inhibit bone bridge formation in a growth plate injury region without a scaffold and differentiate to a growth plate cartilage tissue to effectively fill and regenerate the injured region therewith, whereby the regenerated growth plate tissue can recover growth ability. In addition, the composition is compatible with and safe to biological tissues and is characterized by high reproducibility and homogeneity.
10.WO/2021/011437PEPTIDES AND METHODS FOR TREATING DISEASES
WO - 21.01.2021
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
 Appl.No PCT/US2020/041744 Applicant OP-T LLC Inventor WAGNER, JR., David Hal
Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to β-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD 154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.
# -